Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Lancet Microbe ; 5(5): e452-e458, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38527471

RESUMEN

INTRODUCTION: Continued SARS-CoV-2 infection among immunocompromised individuals is likely to play a role in generating genomic diversity and the emergence of novel variants. Antiviral treatments such as molnupiravir are used to mitigate severe COVID-19 outcomes, but the extended effects of these drugs on viral evolution in patients with chronic infections remain uncertain. This study investigates how molnupiravir affects SARS-CoV-2 evolution in immunocompromised patients with prolonged infections. METHODS: The study included five immunocompromised patients treated with molnupiravir and four patients not treated with molnupiravir (two immunocompromised and two non-immunocompromised). We selected patients who had been infected by similar SARS-CoV-2 variants and with high-quality genomes across timepoints to allow comparison between groups. Throat and nasopharyngeal samples were collected in patients up to 44 days post treatment and were sequenced using tiled amplicon sequencing followed by variant calling. The UShER pipeline and University of California Santa Cruz genome viewer provided insights into the global context of variants. Treated and untreated patients were compared, and mutation profiles were visualised to understand the impact of molnupiravir on viral evolution. FINDINGS: Patients treated with molnupiravir showed a large increase in low-to-mid-frequency variants in as little as 10 days after treatment, whereas no such change was observed in untreated patients. Some of these variants became fixed in the viral population, including non-synonymous mutations in the spike protein. The variants were distributed across the genome and included unique mutations not commonly found in global omicron genomes. Notably, G-to-A and C-to-T mutations dominated the mutational profile of treated patients, persisting up to 44 days post treatment. INTERPRETATION: Molnupiravir treatment in immunocompromised patients led to the accumulation of a distinctive pattern of mutations beyond the recommended 5 days of treatment. Treated patients maintained persistent PCR positivity for the duration of monitoring, indicating clear potential for transmission and subsequent emergence of novel variants. FUNDING: Australian Research Council.


Asunto(s)
Antivirales , Tratamiento Farmacológico de COVID-19 , Citidina , Hidroxilaminas , Huésped Inmunocomprometido , SARS-CoV-2 , Humanos , SARS-CoV-2/genética , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/inmunología , Estudios Retrospectivos , Antivirales/uso terapéutico , Antivirales/farmacología , Hidroxilaminas/uso terapéutico , Hidroxilaminas/farmacología , Masculino , Citidina/análogos & derivados , Citidina/uso terapéutico , Citidina/farmacología , Femenino , Persona de Mediana Edad , Mutación , Anciano , COVID-19/inmunología , COVID-19/virología , Evolución Molecular , Adulto , Genoma Viral/genética
2.
J Clin Neurosci ; 14(2): 116-21, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17107803

RESUMEN

Campylobacter jejuni has been implicated in the pathogenesis of Guillain-Barre syndrome (GBS); however, little information exists on the utility of Campylobacter serology in determining recent infection in the patient population. C. jejuni specific antibodies (CAs) were measured in 420 blood donors (controls), 99 patients with recent C. jejuni infection, 34 patients with central nervous system disorders (neurology controls), and 44 patients with peripheral nervous system (PNS) disorders: 18 with GBS, 12 with MND and 14 with chronic inflammatory neuropathies. Elevated CA titres consistent with recent C. jejuni infection were found in six of the 44 patients with PNS disorders (three with GBS, two with neuropathy, and one with MND, only one of whom had a history of recent C. jejuni infection), compared with two of 454 controls (p = 0.00001). Therefore, we conclude that CAs are often raised in patients with PNS disorders who do not have a history of recent C. jejuni gastroenteritis, so Campylobacter serology may be an unreliable marker of recent infection in this patient group.


Asunto(s)
Anticuerpos Antibacterianos/sangre , Infecciones por Campylobacter/inmunología , Campylobacter jejuni/inmunología , Síndrome de Guillain-Barré/inmunología , Enfermedades del Sistema Nervioso Periférico/inmunología , Enfermedad Aguda , Infecciones por Campylobacter/complicaciones , Infecciones por Campylobacter/diagnóstico , Estudios de Casos y Controles , Síndrome de Guillain-Barré/sangre , Síndrome de Guillain-Barré/complicaciones , Humanos , Enfermedad de la Neurona Motora/sangre , Enfermedad de la Neurona Motora/complicaciones , Enfermedad de la Neurona Motora/inmunología , Enfermedades del Sistema Nervioso Periférico/sangre , Enfermedades del Sistema Nervioso Periférico/complicaciones , Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante/sangre , Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante/complicaciones , Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante/inmunología , Estadísticas no Paramétricas
3.
Health Hum Rights ; 9(1): 80-100, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17061771

RESUMEN

Program managers and researchers promoting children's rights to health, education, and an adequate standard of living often gather data directly from children to assess their needs and develop responsive services. Gathering information within a participatory framework recognizing children's views contributes to protection of their rights. Extra precautions, however, are needed to protect children because of the vulnerabilities associated with their developmental needs. Using case studies of ethical challenges faced by program implementers and sociobehavioral researchers, this article explores ways in which data collection activities among children may affect their rights. We suggest ways in which rights-based principles may be used to derive safeguards to protect against unintentional harm and abuses, based on a multidisciplinary consultation with researchers and service providers.


Asunto(s)
Recolección de Datos/ética , Estado de Salud , Derechos Humanos , Pobreza , Cambodia , Niño , Preescolar , Humanos , Uganda , Zimbabwe
4.
Blood Adv ; 1(2): 132-138, 2016 Dec 13.
Artículo en Inglés | MEDLINE | ID: mdl-29296806

RESUMEN

We report here on a case of ETV6-RUNX1-positive B-cell acute lymphoblastic leukemia (B-ALL) that has acquired a BCR-ABL1 gene rearrangement as a subclonal change. The 19-year-old female patient presented with B symptoms, pancytopenia, and circulating blasts. The bone marrow aspirate was hypercellular and was infiltrated by an immature blast population that was confirmed as B-ALL by flow cytometry. Sequential fluorescent in situ hybridization was performed on the patient's leukemic cells, which were shown to contain both ETV6-RUNX1 and BCR-ABL1 gene rearrangements. The majority of nuclei (85%) showed only the ETV6-RUNX1 gene rearrangement; however, an additional 10% also showed a variant BCR-ABL1 gene rearrangement, indicating the ETV6-RUNX1 gene rearrangement was the primary change. A review of the literature has shown that acquisition of a BCR-ABL1 gene rearrangement as a secondary change in B-ALL is a very rare occurrence, and the effect it may have on prognosis is uncertain in the modern therapy age.

5.
Pathology ; 37(2): 157-9, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16028845

RESUMEN

AIMS: It has been postulated that the recent world-wide increase in the incidence of non-Hodgkin's lymphoma (NHL) may have been caused by human infection with simian virus 40 (SV40) (a lymphotropic monkey virus that was introduced to man from contaminated poliovirus vaccines between 1955 and 1963); therefore, we set out to determine the incidence of SV40 DNA positivity in lymphoma samples from patients in Tasmania, Australia. METHODS: One hundred lymph node samples, 50 from patients with lymphomas and 50 from controls, were tested using PCR amplification of three SV40-specific primer pairs followed by dot-blot hybridisation. RESULTS: All of the samples tested contained amplifiable DNA, but none contained amplifiable SV40 sequences with any of the primer sets used. CONCLUSIONS: Our results demonstrate absence of SV40 in the lymphoid tissues of our study population in Tasmania, Australia. SV40 does not explain the increasing incidence of NHL in our population.


Asunto(s)
ADN Viral/aislamiento & purificación , Linfoma no Hodgkin/virología , Infecciones por Polyomavirus/complicaciones , Virus 40 de los Simios/aislamiento & purificación , Infecciones Tumorales por Virus/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Linfoma no Hodgkin/etiología , Linfoma no Hodgkin/patología , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Infecciones por Polyomavirus/patología , Virus 40 de los Simios/genética , Infecciones Tumorales por Virus/patología
6.
Antiviral Res ; 97(2): 206-10, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23274624

RESUMEN

Despite greater than 99% of influenza A viruses circulating in the Asia-Pacific region being resistant to the adamantane antiviral drugs in 2011, the large majority of influenza A (>97%) and B strains (∼99%) remained susceptible to the neuraminidase inhibitors oseltamivir and zanamivir. However, compared to the first year of the 2009 pandemic, cases of oseltamivir-resistant A(H1N1)pdm09 viruses with the H275Y neuraminidase mutation increased in 2011, primarily due to an outbreak of oseltamivir-resistant viruses that occurred in Newcastle, as reported in Hurt et al. (2011c, 2012a), where the majority of the resistant viruses were from community patients not being treated with oseltamivir. A small number of influenza B viruses with reduced oseltamivir or zanamivir susceptibility were also detected. The increased detection of neuraminidase inhibitor resistant strains circulating in the community and the detection of novel variants with reduced susceptibility are reminders that monitoring of influenza viruses is important to ensure that antiviral treatment guidelines remain appropriate.


Asunto(s)
Antivirales/farmacología , Virus de la Influenza A/efectos de los fármacos , Virus de la Influenza B/efectos de los fármacos , Gripe Humana/virología , Asia , Humanos , Virus de la Influenza A/aislamiento & purificación , Virus de la Influenza B/aislamiento & purificación , Concentración 50 Inhibidora , Pruebas de Sensibilidad Microbiana , Islas del Pacífico
7.
Pediatr Infect Dis J ; 30(12): 1096-5, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21747322

RESUMEN

We describe an outbreak of human rhinovirus type C infection in 7 infants in our neonatal/pediatric intensive care unit. Five infants had clinically significant apneic episodes and 5 required increased oxygen or ventilatory support. Infants shed virus detectable by polymerase chain reaction for a median of 4 weeks.


Asunto(s)
Brotes de Enfermedades , Unidades de Cuidado Intensivo Neonatal/estadística & datos numéricos , Infecciones por Picornaviridae/epidemiología , Rhinovirus/aislamiento & purificación , Australia/epidemiología , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Infecciones por Picornaviridae/virología , Estudios Retrospectivos , Carga Viral
8.
Commun Dis Intell Q Rep ; 29(2): 160-4, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16119764

RESUMEN

The following is a report of an unusual family cluster of group C invasive meningococcal disease in Tasmania. This unusual case cluster raises several important issues of public health significance regarding vaccine failure and nucleic acid amplification testing use in the setting of invasive meningococcal disease.


Asunto(s)
Infecciones Meningocócicas/microbiología , Infecciones Meningocócicas/prevención & control , Vacunas Meningococicas , Adulto , Antibacterianos/uso terapéutico , Niño , Análisis por Conglomerados , Salud de la Familia , Femenino , Humanos , Lactante , Masculino , Infecciones Meningocócicas/tratamiento farmacológico , Tasmania/epidemiología , Insuficiencia del Tratamiento
9.
BJOG ; 109(9): 1050-5, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12269681

RESUMEN

OBJECTIVE: Clinical experience suggests that reflexology may have beneficial effects on the symptoms occurring in menopausal women, particularly psychological symptoms. This study aims to examine that effect rigorously. DESIGN: Randomised controlled trial with two parallel arms. SETTING: School of Complementary Health in Exeter, Devon, UK. SAMPLE: Seventy-six women, aged between 45 and 60 years, reporting menopausal symptoms. METHODS: Women were randomised to receive nine sessions of either reflexology or nonspecific foot massage (control) by four qualified reflexologists given over a period of 19 weeks. MAIN OUTCOME MEASURES: The Women's Health Questionnaire (WHQ), the primary measures being the subscores for anxiety and depression. Severity (visual analogue scale, VAS) and frequency of flushes and night sweats. RESULTS: Mean (SD) scores for anxiety fell from 0.43 (0.29) to 0.22 (0.25) in the reflexology group and from 0.37 (0.27) to 0.27 (0.29) in the control group over the course of treatment. Mean (SD) scores for depression fell from 0.37 (0.25) to 0.20 (0.24) in the reflexology group and from 0.36 (0.23) to 0.20 (0.21) in the control (foot massage) group over the same period. For both scores there was strong evidence of a time effect (P < 0.001) but no evidence of a time-group interaction (P > 0.2). Similar changes were found for severity of hot flushes and night sweats. In the control group, 14/37 believed they had not received true reflexology. CONCLUSION: Foot reflexology was not shown to be more effective than non-specific foot massage in the treatment of psychological symptoms occurring during the menopause.


Asunto(s)
Masaje/métodos , Menopausia/psicología , Anciano , Ansiedad/rehabilitación , Depresión/rehabilitación , Femenino , Rubor/etiología , Humanos , Salud Mental , Persona de Mediana Edad , Encuestas y Cuestionarios , Sudoración , Salud de la Mujer
10.
Am J Epidemiol ; 159(9): 826-33, 2004 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-15105175

RESUMEN

The authors quantified improvement in predicting cutaneous malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin made possible by information on common variants of the melanocortin-1 receptor gene (MC1R) in a 1998-1999 population-based case-control study of subjects aged 20-59 years of northern European ancestry in Tasmania, Australia. Melanin density at the upper inner arm was estimated by spectrophotometry. DNA samples were genotyped for five MC1R variants: Val60Leu, Asp84Glu, Arg151Cys, Arg160Trp, and Asp294His. Among controls (n = 267), variant carriers, versus noncarriers, had lower (p < 0.01) mean melanin concentrations. Increased risk conferred by genotype was restricted mainly to those with the darkest skins: for subjects with at least 2% melanin, the odds of carrying each additional variant were higher for cutaneous malignant melanoma (n = 39; odds ratio = 1.45, 95% confidence interval: 0.87, 2.44), basal cell carcinoma (n = 35; odds ratio = 1.86, 95% confidence interval: 1.14, 3.02), and squamous cell carcinoma (n = 42; odds ratio = 2.67, 95% confidence interval: 1.50, 4.74) cases than for controls (n = 135). Adding MC1R information to prediction based on age, sex, and cutaneous melanin increased the area under the receiver operating characteristic curve by 1.4% (cutaneous malignant melanoma), 3.2% (basal cell carcinoma), or 2.0% (squamous cell carcinoma). The improvement in prediction was probably too small to be valuable in a clinical setting.


Asunto(s)
Carcinoma Basocelular/genética , Carcinoma de Células Escamosas/genética , Predisposición Genética a la Enfermedad/genética , Pruebas Genéticas/métodos , Genotipo , Melanoma/genética , Receptor de Melanocortina Tipo 1/genética , Neoplasias Cutáneas/genética , Adulto , Carcinoma Basocelular/epidemiología , Carcinoma de Células Escamosas/epidemiología , Estudios de Casos y Controles , Femenino , Frecuencia de los Genes , Predisposición Genética a la Enfermedad/epidemiología , Pruebas Genéticas/normas , Variación Genética/genética , Humanos , Masculino , Melaninas/análisis , Melanoma/epidemiología , Persona de Mediana Edad , Vigilancia de la Población/métodos , Valor Predictivo de las Pruebas , Curva ROC , Sistema de Registros , Medición de Riesgo/métodos , Factores de Riesgo , Piel/química , Neoplasias Cutáneas/epidemiología , Espectrofotometría/métodos , Espectrofotometría/normas , Tasmania/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA